MSET Stock Overview
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Mindset Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.74 |
| 52 Week High | CA$0.75 |
| 52 Week Low | CA$0.22 |
| Beta | -0.098 |
| 1 Month Change | 1.37% |
| 3 Month Change | 45.10% |
| 1 Year Change | 76.19% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.00% |
Recent News & Updates
Shareholder Returns
| MSET | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -1.3% | -3.6% | 0.7% |
| 1Y | 76.2% | 54.7% | 5.5% |
Return vs Industry: MSET exceeded the Canadian Pharmaceuticals industry which returned -29.5% over the past year.
Return vs Market: MSET exceeded the Canadian Market which returned -0.7% over the past year.
Price Volatility
| MSET volatility | |
|---|---|
| MSET Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 13.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MSET's share price has been volatile over the past 3 months.
Volatility Over Time: MSET's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | James Lanthier | www.mindsetpharma.com |
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
Mindset Pharma Inc. Fundamentals Summary
| MSET fundamental statistics | |
|---|---|
| Market cap | CA$74.96m |
| Earnings (TTM) | -CA$6.11m |
| Revenue (TTM) | CA$7.75m |
9.7x
P/S Ratio-12.3x
P/E RatioIs MSET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSET income statement (TTM) | |
|---|---|
| Revenue | CA$7.75m |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$7.75m |
| Other Expenses | CA$13.86m |
| Earnings | -CA$6.11m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 100.00% |
| Net Profit Margin | -78.82% |
| Debt/Equity Ratio | 0% |
How did MSET perform over the long term?
See historical performance and comparison